Almirall: Lebrikizumab Shows Long-Term Disease Control in Atopic Dermatitis Study

Almirall announced long-term results from the Phase 3b ADlong extension study evaluating lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis. The study showed long-term disease control for up to five years.